Mounjaro can cause digestive side effects including nausea, bloating, constipation, diarrhoea, indigestion, burping, excessive gas and abdominal discomfort. These symptoms often begin when treatment is started or the dose is increased, and they improve over time for many people.

But what if you are still bloated, constipated or experiencing diarrhoea several weeks, or even months after your final injection?

Digestive symptoms can continue for a short period after stopping Mounjaro because tirzepatide leaves the body gradually. However, symptoms lasting for several months are unlikely to be explained solely by medication remaining in your system.

Possible causes include unresolved constipation, changes in eating habits, delayed stomach emptying, irritable bowel syndrome, reflux, gallbladder problems or, in some people, small intestinal bacterial overgrowth, irritable bowel syndrome or food intolerances.

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, a prescription medicine usually administered as a weekly injection.

Tirzepatide activates receptors for two naturally occurring hormones:

• glucagon-like peptide-1, known as GLP-1;
• glucose-dependent insulinotropic polypeptide, known as GIP.

It is therefore known as a dual GIP and GLP-1 receptor agonist.

Mounjaro helps regulate blood glucose, reduces appetite and increases feelings of fullness after eating. It also delays gastric emptying, meaning that food passes from the stomach into the small intestine more slowly. This effect is generally most pronounced when treatment begins.

In the UK, Mounjaro is prescribed for type 2 diabetes and for weight management in eligible adults alongside dietary and lifestyle changes.

What gastrointestinal side effects can Mounjaro cause?

Digestive symptoms are among the most common side effects of tirzepatide.

These can include:

• nausea;
• diarrhoea;
• constipation;
• vomiting;
• abdominal pain;
• indigestion;
• bloating or abdominal distension;
• excessive wind;
• belching;
• acid reflux;
• reduced appetite;
• feeling full after eating a small amount.

Nausea, diarrhoea, vomiting and constipation are more likely to occur when treatment begins or the dose is increased. They become less frequent over time for many people, although some continue to experience symptoms.

Mounjaro’s effects are not limited to appetite. GLP-1-based medicines can influence motility throughout the gastrointestinal tract, although delayed stomach emptying is the best-established effect. These changes in motility may contribute to nausea, early fullness, indigestion and changes in bowel habits.

Although Mounjaro is often grouped with medicines such as Wegovy and Ozempic, it is not exactly the same. Wegovy and Ozempic contain semaglutide, which acts on GLP-1 receptors, whereas tirzepatide acts on both GIP and GLP-1 receptors.

Nevertheless, these medicines can produce a similar pattern of digestive symptoms.

How long do digestive symptoms last after stopping Mounjaro?

Mounjaro does not leave your body immediately after your final injection.

Tirzepatide has a long elimination half-life, which allows it to be given once a week. This means that its concentration falls gradually over a period of several weeks rather than disappearing overnight.

It is therefore possible for nausea, fullness, constipation or other medication-related symptoms to continue for a while after your last dose.

However, there is no precise, evidence-based timetable that tells us exactly when every digestive symptom should resolve. People respond differently depending on a number of factors including the dose they were taking and duration, their underlying digestive health, whether they were constipated before treatment, other medicines they take, diabetes and blood sugar control what and how much they are eating.

If symptoms continue for several months, it becomes increasingly important to consider whether something else is contributing.

This does not necessarily mean that Mounjaro has permanently damaged your digestive system. It may mean that constipation has not resolved, normal eating patterns have not returned or another digestive condition has become more noticeable.

Why am I still bloated after stopping Mounjaro?

Bloating after Mounjaro can have several possible explanations. When stomach emptying is delayed, food and liquid remain in the upper digestive tract for longer and may contribute to bloating.

This can make your abdomen feel full or stretched, particularly after eating. You may notice that even a relatively small meal leaves you feeling uncomfortable for several hours.

Bloating caused by delayed stomach emptying is often felt in the upper abdomen.

Constipation may be creating gas and pressure

Constipation is one of the most common causes of continuing bloating.

You do not need to stop opening your bowels completely to be constipated. You may still pass stool regularly but experience hard or lumpy stools and incomplete emptying.

When bowel contents move slowly, intestinal bacteria have more time to ferment them. This can increase gas production and make the abdomen feel swollen or uncomfortable.

Tirzepatide may still be in your body

If your last injection was less than four or five weeks ago, Mounjaro may still be affecting how quickly food moves through your stomach and digestive tract.

Slower gastric emptying can cause:

• prolonged fullness;
• nausea;
• upper abdominal pressure;
• belching;
• reflux;
• bloating after eating.

Your appetite may have returned quickly

As the effects of Mounjaro wear off, you may become hungrier and begin eating larger meals.

A sudden return to larger portions, richer foods or high-fat meals may increase fullness, nausea, reflux and abdominal discomfort before your digestion has fully readjusted.

You may be eating more fermentable carbohydrates

When appetite returns, you may also eat larger amounts of wheat, pulses, fruit, vegetables or dairy products.

These are not inherently unhealthy foods. However, they contain carbohydrates that can be fermented by intestinal bacteria, potentially increasing gas in people with IBS, SIBO or lactose intolerance.

A separate digestive condition may be present

Persistent bloating may also be related to:

• SIBO;
• IMO;
• IBS;
• lactose intolerance;
• chronic constipation;
• delayed gastric emptying;
• coeliac disease;
• bile-acid diarrhoea;n.

The same symptom can have several causes, which is why testing should be selected according to your full symptom pattern rather than bloating alone.

Could persistent symptoms after Mounjaro be SIBO?

Small intestinal bacterial overgrowth, or SIBO, occurs when bacteria are present in excessive numbers or in an abnormal distribution within the small intestine.

The small intestine normally contains fewer bacteria than the colon. Several mechanisms help keep bacterial numbers under control, including stomach acid, bile, pancreatic secretions, the immune system and normal intestinal movement.

If movement through the small intestine becomes impaired, bacteria and fermentable carbohydrates may remain in contact for longer. The bacteria can then ferment carbohydrates before they are fully absorbed, producing hydrogen and Methane.

Possible SIBO symptoms include:

• bloating that worsens after meals;
• excessive wind;
• abdominal distension;
• abdominal pain or cramping;
• diarrhoea or loose stools;
• nausea;
• alternating diarrhoea and constipation;
• increased sensitivity to certain carbohydrates.

Mounjaro has not been proven to directly cause SIBO. However, reduced gastrointestinal motility is a plausible mechanism through which GLP-1-based medicines might increase susceptibility in some people.

A large retrospective study published in 2025 found a higher short-term rate of diagnosed SIBO among people using GLP-1 receptor agonists or dual GLP-1/GIP medicines than among matched patients using other diabetes treatments. However, the absolute number of diagnoses was very small, several medicines were grouped together and the study could not prove causation.

A separate 2025 study also found an association between GLP-1 receptor agonist use and SIBO or Intestinal Methanogen Overgrowth.

The authors acknowledged that diabetes itself could have influenced the findings because diabetes can also affect gastrointestinal motility.

The evidence therefore suggests a possible association, not proof that Mounjaro directly causes SIBO.

Could constipation after Mounjaro be intestinal methanogen overgrowth?

Intestinal methanogen overgrowth, usually abbreviated to IMO, is associated with excessive methane production in the digestive tract.

Methane is produced by microorganisms called archaea rather than bacteria, which is why IMO is technically different from SIBO.

IMO is particularly associated with slower intestinal transit and constipation.

Possible symptoms include:

• persistent constipation;
• hard or infrequent stools;
• substantial abdominal bloating;
• abdominal distension;
• trapped wind;
• straining;
• a feeling of incomplete emptying.

If you were already prone to constipation before starting Mounjaro, slower digestion during treatment may have made the problem more noticeable.

However, constipation after Mounjaro does not automatically mean that you have IMO. Other common causes include inadequate fluid intake, eating too little, low fibre intake, reduced movement and medications that slow the bowel.

A hydrogen and methane breath test may be worth considering when constipation is persistent and accompanied by pronounced bloating or distension.

Could the symptoms be IBS?

Irritable bowel syndrome, or IBS, is a disorder of gut–brain interaction. It usually involves recurring abdominal pain associated with a change in stool frequency or consistency.

IBS may cause:

• bloating;
• abdominal pain;
• constipation;
• diarrhoea;
• alternating constipation and diarrhoea;
• urgency;
• incomplete evacuation;
• mucus in the stool.

Mounjaro can cause symptoms that resemble IBS, including abdominal discomfort and altered bowel habits. It may also make previously mild IBS symptoms more noticeable.

However, there is currently no good evidence that stopping Mounjaro directly causes IBS.

If abdominal pain and bowel changes continue after tirzepatide has largely left your body, it may be appropriate to assess whether IBS or another digestive condition is contributing.

IBS is not diagnosed from one symptom or from a breath test. A proper assessment should also consider red-flag symptoms and conditions such as coeliac disease, inflammatory bowel disease, infection and bile-acid diarrhoea. If you need help with IBS please visit our sister clinic ibs and gut disorder

Could it be lactose intolerance?

Lactose intolerance occurs when the small intestine does not produce enough lactase, the enzyme needed to break down lactose, the natural sugar found in milk.

When lactose is not fully digested, it travels into the colon, where bacteria ferment it. This can cause:

• bloating;
• excessive wind;
• abdominal rumbling;
• diarrhoea;
• urgency;
• abdominal pain after dairy products.

There is no established evidence that stopping Mounjaro directly causes lactose intolerance.

However, you may first notice symptoms after Mounjaro for several reasons.

Your food intake may have changed, you may be consuming more dairy as your appetite returns, or you may have had mild lactose malabsorption before treatment that did not previously cause obvious symptoms.

IBS can also make you more sensitive to the gas and distension produced when lactose is fermented.

This is one reason why ordering the right tests in the right sequence is important.

Symptoms after onions, garlic, wheat or pulses

These foods contain fermentable carbohydrates known as FODMAPs.

Reactions may occur in IBS or SIBO, but symptoms after FODMAP foods cannot distinguish between the two. These foods are nutritious and should not automatically be removed long term.

How are SIBO and IMO tested?

SIBO and IMO are commonly investigated using a hydrogen and methane breath test.

After following a preparation diet and an overnight fast, you provide a baseline breath sample and drink a measured quantity of glucose or lactulose. Further samples are collected over the next two to three hours.

You can order a SIBO test

How is lactose intolerance tested?

Lactose malabsorption can also be investigated with a hydrogen and methane breath test.

You drink a measured lactose solution and provide breath samples over a set period. A rise in gas suggests that lactose was not fully absorbed before being fermented by intestinal microorganisms.

When might a digestive consultation be helpful?

A consultation may be useful if you are still experiencing:

• persistent bloating after stopping Mounjaro;
• severe abdominal distension after meals;
• constipation accompanied by trapped wind;
• diarrhoea or urgent bowel movements;
• alternating constipation and diarrhoea;
• abdominal pain associated with bowel changes;
• increased reactions to carbohydrates;
• bloating, wind or diarrhoea after dairy;
• symptoms that have not improved several weeks after your final dose.

Should you follow a low-FODMAP diet after stopping Mounjaro?

A temporary low-FODMAP approach can reduce bloating and bowel symptoms in some people with IBS.

When appetite has already been reduced by Mounjaro, removing numerous foods can make it harder to consume enough energy, protein, fibre, vitamins and minerals.

Before restricting your diet, it is helpful to establish:

• which foods are actually causing symptoms;
• whether constipation is the main problem;
• whether dairy symptoms are due to lactose;
• whether SIBO or IMO testing is appropriate;
• whether another medical condition needs to be excluded.

How can you support digestion after stopping Mounjaro?

While waiting for symptoms to improve or be assessed, the following may help.

Increase meal size gradually

As your appetite returns, avoid immediately moving from very small meals to large portions.

A sudden increase in meal size can worsen fullness, reflux and bloating.

Eat slowly

Eating quickly can increase swallowed air and make belching, abdominal pressure and bloating worse.

Drink regularly

Adequate fluid is particularly important if you have constipation or diarrhoea.

Increase fibre carefully

Fibre can support regular bowel movements, but increasing it too quickly may worsen bloating, particularly if intestinal transit is slow.

Cooked vegetables, oats, kiwi fruit and ground linseeds may be easier for some people to tolerate than large quantities of bran or raw vegetables.

Avoid unnecessary food restriction

Do not remove gluten, dairy, fruit and vegetables simply because you feel bloated.

Symptoms after dairy may be caused by lactose, but symptoms could also reflect IBS, SIBO or the fat content of the meal. Testing and a structured food trial can provide more useful information than excluding multiple food groups indefinitely.

Need Support With Symptoms? Book a consultation

If you’re struggling with methane overgrowth and would like professional support, you can book a consultation at our sister clinic,

ibs-solutions.co.uk

You can book a consultation, arrange SIBO testing, or request a call to discuss your symptoms and next steps.

 
Book a consultation with a SIBO specialist today.

Author – Victoria Tyler BSc Hons MBANT

Victoria Tyler owns and runs two busy clinics : Nutrition and Vitality and the IBS and Gut Disorder Clinic.

Nutrition and Vitality, along with the IBS and Gut Disorder Clinic, were founded with the goal of helping patients alleviate IBS symptoms by uncovering and addressing the root causes of their digestive issues.

As a Registered Nutritional Therapist, Victoria holds a BSc (Hons) in Nutritional Therapy and has trained with the Institute of Functional Medicine. She is also accredited by BANT and CNHC.

Before transitioning into health, Victoria earned a degree in Economics and an MBA, working with corporations including Canon and Vodafone. However, her own health challenges led her to pursue a career in Nutritional Therapy.

With a passion for learning, Victoria is committed to staying at the forefront of Functional Medicine. She helps patients manage IBS and other digestive disorders, including SIBO, Candida, and IBD, by identifying and addressing their root causes.

Victoria strongly believes that every symptom has an underlying cause, and there is always a solution to every health condition. To learn more, or to see patient reviews, visit Victoria’s profile on Google.

DISCLAIMER: The information provided in this article is intended for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment. The products and methods mentioned are not a substitute for professional medical advice from a trained healthcare specialist. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Use of the information and products discussed is at your own risk.

References

He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y. and Xu, L. (2022) ‘Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials’, JAMA Internal Medicine, 182(5), pp. 513–519. doi: 10.1001/jamainternmed.2022.0338.

Jalleh, R.J., Jones, K.L., Rayner, C.K., Marathe, C.S., Wu, T. and Horowitz, M. (2024) ‘Gastrointestinal effects of GLP-1 receptor agonists: Mechanisms, clinical consequences and management’, The Lancet Gastroenterology & Hepatology, 9(8), pp. 740–753.

Maselli, D.B. and Camilleri, M. (2021) ‘Effects of GLP-1 and its analogues on gastric physiology in diabetes mellitus and obesity’, Advances in Experimental Medicine and Biology, 1307, pp. 171–192. doi: 10.1007/5584_2020_496.

Patel, H., Khunti, K., Rodbard, H.W., Bajaj, H.S., Bray, R., Kindracki, Z. and Rodríguez, Á. (2024) ‘Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials’, Diabetes, Obesity and Metabolism, 26(2), pp. 473–481. doi: 10.1111/dom.15333.

Sun, Y. et al. (2025) ‘Diagnostic evaluation of an increased risk of developing small intestinal bacterial overgrowth associated with glucagon-like peptide-1 receptor agonists and dual GLP-1/GIP receptor agonists’, Diagnostics, 15. doi: 10.3390/diagnostics15182185.

Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D.M., Pedersen, S.D. and Kushner, R.F. (2022) ‘Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss’, Diabetes, Obesity and Metabolism, 24(1), pp. 94–105. doi: 10.1111/dom.14551.

Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A., Wharton, S., Yokote, K. and Kushner, R.F. (2021) ‘Once-weekly semaglutide in adults with overweight or obesity’, New England Journal of Medicine, 384(11), pp. 989–1002. doi: 10.1056/NEJMoa2032183.

Chaudhry, A., Gabriel, A. and Noor, J. (2024) ‘Tendency of semaglutide to induce gastroparesis: A case report’, Cureus, 16(1), e52091. doi: 10.7759/cureus.52091.

Kalas, M.A., Galura, G.M., McCallum, R.W. and Grover, M. (2021) ‘Medication-induced gastroparesis: A case report’, Journal of Investigative Medicine High Impact Case Reports, 9, pp. 1–4. doi: 10.1177/23247096211051919.

Ghusn, W. et al. (2024) ‘Discontinuing semaglutide after weight loss: Strategy for weight maintenance and a possible association with small intestinal bacterial overgrowth’, Canadian Journal of Physiology and Pharmacology, 102(5), pp. 304–308. doi: 10.1139/cjpp-2023-0464.

Maselli, D.B., Camilleri, M., Acosta, A., Vazquez-Roque, M.I., Boldingh, A., Burton, D., Carlson, P. and Zinsmeister, A.R. (2024) ‘Quantified metrics of gastric emptying delay by glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis with insights for periprocedural management’, American Journal of Gastroenterology, 119(7), pp. 1126–1140.